Product logins

Find logins to all Clarivate products below.


: Drugs to Watch

Here you will find relevant articles and insight into all Clarivate related products and news.

Antibody drug conjugates and bispecifics seize the spotlight at ASCO 2022 Antibody drug conjugates and bispecifics seize the spotlight at ASCO 2022
Blog June 23, 2022
Antibody drug conjugates and bispecifics seize the spotlight at ASCO 2022
Clinical research Clinical trials Drugs to Watch
Expected blockbusters: A year in progress Expected blockbusters: A year in progress
Blog November 18, 2019
Expected blockbusters: A year in progress
Drugs to Watch
Blog October 18, 2018
Roche’s Hemlibra: Market expansion approved, but safety an initial concern?
Drugs to Watch
Blog September 19, 2018
Shire’s Takhzyro expected to dominate in hereditary angioedema
Drugs to Watch Portfolio strategy Rare diseases
Blog September 6, 2018
Sales forecasts rise for AbbVie’s elagolix following expected approval in endometriosis
Drugs to Watch Portfolio strategy
Blog June 7, 2018
Pfizer and Merck's Steglatro for type 2 diabetes: a valuable addition to the rapidly rising SGLT-2 inhibitor market
Drugs to Watch Portfolio strategy
Blog May 2, 2018
Novo Nordisk’s Ozempic: Launch was late but sales forecasts climbing
Drugs to Watch Portfolio strategy
Blog April 18, 2018
GSK's Shingrix set to become the market leading shingles vaccine
Drugs to Watch Portfolio strategy Research and development

Drugs to Watch

온디맨드 웨비나 사이트런칭 온디맨드 웨비나 사이트런칭
Blog March 15, 2022
온디맨드 웨비나 사이트런칭
Antibody drug conjugates and bispecifics seize the spotlight at ASCO 2022 Antibody drug conjugates and bispecifics seize the spotlight at ASCO 2022
Blog June 23, 2022
Antibody drug conjugates and bispecifics seize the spotlight at ASCO 2022
Expected blockbusters: A year in progress Expected blockbusters: A year in progress
Blog November 18, 2019
Expected blockbusters: A year in progress
Blog October 18, 2018
Roche’s Hemlibra: Market expansion approved, but safety an initial concern?
Blog September 19, 2018
Shire’s Takhzyro expected to dominate in hereditary angioedema
Blog September 6, 2018
Sales forecasts rise for AbbVie’s elagolix following expected approval in endometriosis
Blog June 7, 2018
Pfizer and Merck's Steglatro for type 2 diabetes: a valuable addition to the rapidly rising SGLT-2 inhibitor market
Blog May 2, 2018
Novo Nordisk’s Ozempic: Launch was late but sales forecasts climbing
Blog April 18, 2018
GSK's Shingrix set to become the market leading shingles vaccine
Blog April 26, 2017
Roche’s Ocrevus to dominate the multiple sclerosis market